In one paragraphArticle in Molecular systems biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
16 authors.
Charlie George Barker *European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus, Hinxton, Cambridgeshire, CB10 1SD, UK.
Ana Mafalda SantosRadcliffe Department of Clinical Medicine and Medical Research Council, Translational Immune Discovery Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0002-0015-5286 Konstantinos-Stylianos NikolakopoulosSection of Cell Biology and Biophysics, Department of Biology, School of Science, National and Kapodistrian University of Athens (NKUA), Athens, 15701, Greece.ORCID http://orcid.org/0009-0001-6694-6558 Athanassios D VelentzasSection of Cell Biology and Biophysics, Department of Biology, School of Science, National and Kapodistrian University of Athens (NKUA), Athens, 15701, Greece.ORCID http://orcid.org/0000-0002-9755-395X Cristina Tormo-GarciaRadcliffe Department of Clinical Medicine and Medical Research Council, Translational Immune Discovery Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.ORCID http://orcid.org/0009-0005-6162-2166 Anushka SharmaRadcliffe Department of Clinical Medicine and Medical Research Council, Translational Immune Discovery Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.ORCID http://orcid.org/0009-0002-1141-9715 Franziska I VöllmyBiomolecular Mass Spectrometry and Proteomics, Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.ORCID http://orcid.org/0000-0002-0345-1910 Angeliki MiniaProtavio, Demokritos Technology Park, Building 27, Patriarchou Grigoriou & Neapoleos 27, Aghia Paraskevi, Attiki, 15341, Greece.
Vicky PliakaProtavio, Demokritos Technology Park, Building 27, Patriarchou Grigoriou & Neapoleos 27, Aghia Paraskevi, Attiki, 15341, Greece.
Joseph ClarkeRadcliffe Department of Clinical Medicine and Medical Research Council, Translational Immune Discovery Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.ORCID http://orcid.org/0009-0009-7631-4464 Maarten AltelaarBiomolecular Mass Spectrometry and Proteomics, Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.ORCID http://orcid.org/0000-0001-5093-5945 Leonidas G AlexopoulosProtavio, Demokritos Technology Park, Building 27, Patriarchou Grigoriou & Neapoleos 27, Aghia Paraskevi, Attiki, 15341, Greece.
Dimitrios J StravopodisSection of Cell Biology and Biophysics, Department of Biology, School of Science, National and Kapodistrian University of Athens (NKUA), Athens, 15701, Greece.ORCID http://orcid.org/0000-0002-9535-2134 Evangelia PetsalakiEuropean Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus, Hinxton, Cambridgeshire, CB10 1SD, UK. petsalaki@ebi.ac.uk.ORCID http://orcid.org/0000-0002-8294-2995 Funding
EMBL International PhD Programme NAEuropean Commission (EC) EU Horizon 2020 program INFRAIA project Epic-XS 823839European Molecular Biology Laboratory (EMBL) NAWellcome Trust 206194Wellcome Trust (WT) 317519/Z/24/Z
6 · The paper itselfAbstract
Resistance to BRAF/MAPK inhibitors is a significant challenge in melanoma treatment, driven by adaptive and acquired mechanisms allowing tumor cells to evade therapy. We explored early signaling responses to BRAF and MAPK inhibition in a BRAFV600E-sensitive melanoma cell line and a drug-resistant ARID1A-knockout (KO) derivative. ARID1A, frequently mutated in melanoma, is linked to resistance and immune evasion. Through an innovative systems biology approach integrating multi-omics datasets, we identified critical resistance mechanisms. We found that ARID1A-KO cells exhibited transcriptional rewiring, sustaining MAPK1/3 and JNK activity post-treatment, suppressing PRKD1 activation, increasing JUN activity, and disrupting PKC dynamics via elevated RTKs (e.g., EGFR, ROS1) and Ephrin receptor activity. ARID1A-KO also reduced HLA-related protein expression and enhanced extracellular matrix components, potentially limiting immune infiltration and immunotherapy efficacy. Our multi-omics analysis revealed PRKD1, JUN, and NCK1 as key resistance nodes, offering potential targets for therapeutic strategies to counter resistance in melanoma.
Indexed as
DNA-Binding ProteinsDrug Resistance, NeoplasmMelanomaTranscription FactorsCell Line, TumorGene Expression Regulation, NeoplasticGene Regulatory NetworksHumansMultiomicsProtein Kinase InhibitorsProto-Oncogene Proteins B-rafSignal TransductionSystems BiologyARID1A protein, humanBRAF protein, humanDNA-Binding ProteinsProtein Kinase InhibitorsProto-Oncogene Proteins B-rafTranscription FactorsARID1AData IntegrationDrug ResistanceMelanomaNetwork Analysis
Identifiers
PMID41708984
PMCPMC13144321
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390